
GxP, cold chain, traceability, Big Four audits. These are the non-negotiable requirements that ensure the IT VP in Lyon or Toulouse can sleep soundly.
Whether from Lyon, Basel, or Barcelona, your European IT director doesn’t view Mexico as just another subsidiary. They see a complex regulatory landscape, a critical supply chain, and a risk point that could jeopardize the approval of an EMA, FDA COFEPRIS audit COFEPRIS a matter of weeks. When a batch is held up due to a lack of digital traceability, when a validation system fails a Big Four audit, or when temperature data from a shipment isn’t properly recorded, the impact is felt throughout the entire corporation.
The pressure faced by the IT manager of a Mexican pharmaceutical subsidiary is real and growing. The demands from the parent company are not mere bureaucratic whims: they stem from binding regulatory frameworks such as Good Manufacturing Practices (GMP), the FDA 21 CFR Part 11 requirements FDA the European guidelines for the validation of computerized systems (GAMP 5). Understanding what your headquarters is the first step toward moving beyond a defensive stance and beginning to operate with confidence.
When the headquarters refers to “IT for compliance,” it is referring to three pillars that leave no room for interpretation:
If any of these three pillars show signs of weakness, your headquarters will know about it before you even notice. And it will document it.
Mexico is a high-risk logistics environment for the pharmaceutical sector: heat, humidity, long distances, and inconsistent infrastructure. The headquarters is aware of this and requires a monitoring infrastructure that leaves no room for doubt:
It's not just about having sensors. It's about demonstrating that the data generated is reliable, auditable, and comparable to the records at headquarters. If your infrastructure can't answer that question automatically, it's an active risk.
Global audit firms—Deloitte, PwC, EY, and KPMG—are conducting increasingly technical reviews when auditing pharmaceutical subsidiaries in Latin America. It is no longer enough to simply demonstrate procedures; they now require access to systems, review logs, verify access controls, and confirm that documented processes match what actually happens on the production floor.
Areas where Mexican subsidiaries often fall short include: poor management of privileged access, backups without documented restoration tests, systems no longer supported by the manufacturer, and the lack of an up-to-date inventory of critical IT assets. Preparing for a Big Four audit isn’t a two-week sprint: it’s the result of operational maturity built up over months in advance.
After 30 years of supporting European subsidiaries in Mexico, Keptos developed a structured assessment that covers the critical areas that every headquarters reviews. This is the framework we apply:
If your headquarters is scheduling an audit, if you've just received a corporate quality questionnaire, or if you simply know that your IT infrastructure isn't where it should be, now is the time to act.
In Keptos, we conduct pharma-IT assessments specifically designed for Mexican subsidiaries of European groups. We understand the standards your headquarters , the criteria used by audit firms, and the areas where local organizations are typically at risk. The result is an actionable report, in Spanish and in your corporate language, that allows you to present a concrete plan to your management.
Request your specialized Keptos assessment and turn the next audit cycle into an opportunity to demonstrate operational maturity to your headquarters .
30 minutes with one of our directors. No sales pitch—straight to the point.